Advances in molecular targeted therapy and biochemotherapy in oncology

Chinese Journal of Cancer Biotherapy

Volumn 16, Issue 2, 2009, Pages 101-105

  Luo, Rong Cheng ^a   Yao, Guang Yu ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Biochemotherapy; Chemotherapy; Evaluation of response; Immunotherapy; Reversal of drug resistance; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT;

BIOCHEMOTHERAPY; CANCER CHEMOTHERAPY; IMMUNOTHERAPY; ONCOLOGY; REVIEW;

EID: 77953414959     PISSN: 1007385X     EISSN: None     Source Type: Journal    
DOI: 10.3872/j.issn.1007-385X.2009.02.001     Document Type: Review

References (25)

1. Chinese source.
2. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target [J]. Ann Oncol, 2008, 19 (9): 1523-1529.
3. Rocha-Lima CM, Soares HP, Raez LE, et al. EGFR targeting of solid tumors [J]. Cancer Control, 2007, 14(3): 295-304.
4. Thome S, Hobday T, Hillman D, et al. Translational correlates, including outcome for patients with ER-/PR-/HER2-(triple negative (TNeg)) disease from N0234, a phase II trial of gemcitabine and erlotinib for pts with previously treated metastatic breast cancer (MBC) [EB/OL]. (2007) [2009-04-21]. http://meeting.ascopubs.org/cgi/content/ abstract/25/18_suppl/1071.
5. Muñoz A, Salut A, Pericay C, et al. Phase II trial of capecitabine, oxaliplatin plus bevacizumab followed by bevacizumab plus erlotinib: XELOBER trial [EB/OL]. (2008) [2009-04-21]. http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/ 15078?maxtoshow=&HITS=20&hits=20&RESULTFORMAT=&fulltext= c.pericay&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT.
6. Von Minckwitz G, Zielinski C, Maartense E, et al. Capecitabine vs capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment [EB/ OL]. (2008) [2009-04-21]. http://meeting.ascopubs.org/cgi/content/ abstract/26/15_suppl/1025.
7. Cancello G, Montagna E, D'Agostino D, et al. Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer [J]. Breast Cancer Res, 2008, 10 (4): R60.
8. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J]. N EngI J Med, 2004, 351 (4): 337-345.
9. Milani M, Harris AL. Targeting tumour hypoxia in breast cancer [J]. Eur J Cancer, 2008, 44(18): 2766-2773.
10. Rho JK, Choi YJ, Lee JK, et al. Gefitinib circumvents hypoxia-induced drug resistance by the modulation of HIF-1 alpha [J]. Oncol Rep, 2009, 21(3): 801-807.
11. Hallaert DY, Jaspers A, van Noesel CJ, et al. c-AbI kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches [J]. Blood, 2008, 112(13): 5141-5149.
12. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls [J]. Nat Rev Drug Discov, 2009, 8(1): 33-40.
13. Azuma H, Tomita N, Sakamoto T, et al. Marked regression of liver metastasis by combined therapy of ultrasound-mediated NF kappaB-decoy transfer and transportal injection of paclitaxel, in mouse [J]. Int J Cancer, 2008, 122(7): 1645-1656.
14. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer [J]. N Engl J Med, 2008, 359(17): 1757-1765.
15. McNeil C. K-Ras mutations are changing practice in advanced colorectal cancer [J]. J Natl Cancer Inst, 2008, 100(23): 1667-1669.
16. Bertolini F, Mancuso P, Curigliano G, et al. The (last?) word about biomarkers for angiogenesis [EB/OL]. (2009) [2009-04-21]. http://ex2.excerptamedica.com/ciw-09ptebc/index.cfm?fuseaction= CIS2002&hoofdnav=Abstracts&content=abs.details&what= AUTHOR&searchtext=goldhirsch&topicselected=*&selection= ABSTRACT&qryStartRowDetail=1.
17. Gennari A, Pronzato P. New understanding of the role of anthracyclines in early-stage breast cancer: patient selection considerations [J]. Clin Breast Cancer, 2008, 8(Suppl 4): S179-S183.
18. Sinkovics JG, Horvath JC. Evidence accumulating in support of cancer vaccines combined with chemotherapy: a pragmatic review of past and present efforts [J]. Int J Oncol, 2006, 29(4): 765-777.
19. Brune M, Castaigne S, Catalano J, et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial [J]. Blood, 2006, 108(1): 88-96.
20. Kimura H, Iizasa T, Ishikawa A, et al. Prospective phase II study of post-surgical adjuvant chemo-immunotherapy using autologous dendritic cells and activated killer cells from tissue culture of tumor-draining lymph nodes in primary lung cancer patients [J]. Anticancer Res, 2008, 28(2B): 1229-1238.
21. King DM. The radiology of gastrointestinal stromal tumours (GIST) [J]. Cancer Imaging, 2005, 5: 150-156.
22. Goffin J, Baral S, Tu D, et al. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval [J]. Clin Cancer Res, 2005, 11(16): 5928-5934.
23. 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab [J]. Gastric Cancer, 2007, 10(4): 221-227.
24. 18F] fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer [J]. J Clin Oncol, 2007, 25(23): 3440-3447.
25. 18F] fluorothymidine positron emission tomography: a pilot study [J]. J Clin Oncol, 2007, 25(30): 4714-4721.